(NewsDirect)
Compumedics Ltd (ASX:CMP) CFO and company secretary David Lawsontalks to Proactive’s Jonathan Jackson about the company’s recordrevenues of at least $46 million for FY24, with sales orders exceeding$50 million. The company anticipates a profit for FY24 due to strongsales performance. Compumedics has projected record sales orders andrevenues for FY24 driven by strong growth in its Australian sleep andneurodiagnostic businesses. The company has received new MEG ordersand has seen increased European sales, particularly boosted by theOkti wireless EEG amplifier. In the USA, sales growth reached 60% inH2 FY24. Compumedics reported an H1 FY24 EBITDA of $2.2 million,though there is uncertainty in meeting the prior guidance of $5million due to investments in the US sales and marketing team anddelays in resuming DWL's China business. In the Somfitcommercialisation update, Compumedics expects SaaS revenue to exceed$4 million for FY24, up from $1.7 million in FY23. Sales havecommenced in the USA following FDA approval, with initial revenuesinvoiced in Q4 FY24. Both Somfit and Nexus 360 show significantrevenue growth. For MEG, the installation at Tianjin Normal Universityin China is expected to be completed soon, with two additional MEGsales planned for 2025. These sales represent about $14 million in neworders.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.